Wave Life Sciences, Inc. (WVE) stock
WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3039% below fair value
$3.13−0.02 (-0.79%)
Close on Nov 13, 2026Market cap $617.33MP/E –Yield –
Wave Life Sciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Wave Life Sciences's ebitda for the twelve months ending Dec 31, 2016 was -$54.94M. For fiscal 2017 it was -$100.24M. The highest annual figure on record is -$3.30M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | -$100.24M | – |
| FY2016 | Dec 31, 2016 | -$54.94M | – |
| FY2015 | Dec 31, 2015 | -$18.70M | – |
| FY2014 | Dec 31, 2014 | -$5.11M | – |
| FY2013 | Dec 31, 2013 | -$3.30M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2016 | Dec 31, 2016 | -$18.25M | – |
See a number that looks wrong?